Maravai Lifesciences Holdings (MRVI) EBITDA Margin (2020 - 2026)
Maravai Lifesciences Holdings' (MRVI) quarterly EBITDA Margin came in at 3.28% in Q1 2026, up 10166.0% year-on-year from N/an in Q1 2025, and up 97.22% quarter-over-quarter from 117.91% in Q4 2025.
Maravai Lifesciences Holdings (MRVI) EBITDA Margin (2020 - 2026) Analysis & Trends
Maravai Lifesciences Holdings' EBITDA Margin history runs 7 years deep, the most recent figure standing at 3.28% for Q1 2026.
- On a quarterly basis, EBITDA Margin rose 10166.0% year-over-year to 3.28% in Q1 2026; TTM through Mar 2026 was 82.19%, a 2776.0% increase from a year earlier, with the FY2025 full-year figure at 115.89%, down 2499.0% from the prior year.
- EBITDA Margin climbed to 3.28% in Q1 2026 per MRVI's latest filing, from 117.91% in the prior quarter.
- Across five years, EBITDA Margin topped out at 74.44% in Q2 2022 and bottomed at 239.93% in Q3 2024.
- The 5-year median for EBITDA Margin is 19.36% (2024), against an average of 35.81%.
- Across the five-year window, EBITDA Margin sank 21688 bps in 2024 and jumped 14137 bps in 2025, its largest moves.
- Year by year, EBITDA Margin stood at 53.37% in 2022, then plunged by 118 bps to 9.64% in 2023, then tumbled by 591 bps to 66.66% in 2024, then tumbled by 77 bps to 117.91% in 2025, then surged by 97 bps to 3.28% in 2026.
- Per Business Quant, the three latest MRVI EBITDA Margin figures stand at 3.28% (Q1 2026), 117.91% (Q4 2025), and 98.56% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Maravai Lifesciences Holdings | 1.03 Bn | 1.02 Bn | 33.70 Mn | -3.28% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.28% |
| Dec 31, 2025 | -117.91% |
| Sep 30, 2025 | -98.56% |
| Jun 30, 2025 | -139.84% |
| Mar 31, 2025 | -104.93% |
| Dec 31, 2024 | -66.66% |
| Sep 30, 2024 | -239.93% |
| Jun 30, 2024 | -19.36% |
| Mar 31, 2024 | -29.39% |
| Dec 31, 2023 | -9.64% |
| Sep 30, 2023 | -23.06% |
| Jun 30, 2023 | -16.85% |
| Mar 31, 2023 | 3.21% |
| Dec 31, 2022 | 53.37% |
| Sep 30, 2022 | 61.12% |
| Jun 30, 2022 | 74.44% |
| Mar 31, 2022 | 68.51% |
| Dec 31, 2021 | 67.65% |
| Sep 30, 2021 | 75.87% |
| Jun 30, 2021 | 70.50% |